Eltrombopag-related liver problems in immune thrombocytopenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study follows adults with primary ITP who are receiving eltrombopag and have normal baseline liver tests to measure new liver dysfunction. Participants will undergo regular liver function testing during treatment to record the incidence and severity of abnormalities. People with pre-existing liver disease or on other hepatotoxic drugs are excluded, and patients lost to follow-up are removed from analysis. The study will collect and report frequency and severity of LFT changes at Sohag University Hospital to inform safer use of eltrombopag.

Why it matters

Who can join: the full rules

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion Criteria:

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Where it's running

• Sohag university hospital
  Sohag, Egypt Recruiting

Study contacts

• Study coordinator: Peter A Alfy, Resident
• Email: peter.adel.dola@gmail.com
• Phone: 01274069691

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multi-target drugs sequentially combine therapy in adults with newly diagnosed immune thrombocytopenia

  This study tests whether starting with standard steroids plus a TPO-RA, then adding a second targeted therapy if needed, can improve platelet counts in adults with newly diagnosed ITP.

  Recruiting Phase 4 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07788456

• CTX112 (zugo-cel) for relapsed/refractory ITP and wAIHA in adults

  This trial tests CTX112, an off-the-shelf CD19 CAR-T therapy, to see if it can help adults with relapsed or refractory ITP or wAIHA.

  Recruiting at 12 sites Phase 1/2 CRISPR Therapeutics · Boston, Massachusetts and 11 other locations · NCT07549698

• Efgartigimod IV for adolescents (12–17) with chronic immune thrombocytopenia

  This trial will try intravenous efgartigimod to see if it safely raises platelet counts in people aged 12 to 17 with chronic ITP.

  Recruiting at 26 sites Phase 2/3 argenx · Bordeaux and 25 other locations · NCT07194850

• Lower starting dose of avatrombopag for immune thrombocytopenia (ITP)

  This pilot will try a lower starting dose of avatrombopag to raise platelet counts in adults with primary ITP who need second-line treatment.

  Recruiting Phase 4 Al-Mustansiriyah University · Baghdad · NCT07133659

• OM336 for autoimmune hemolytic anemia and immune thrombocytopenia

  This phase 1 trial will test whether subcutaneously given OM336 is safe and tolerable in adults with relapsed or refractory autoimmune hemolytic anemia or immune thrombocytopenia.

  Recruiting at 7 sites Phase 1 Lakefront Biotherapeutics West LLC · Duarte, California and 6 other locations · NCT07083960

• Registry for patients with Primary Immune Thrombocytopenia in Spain

  This study is collecting information from patients with Primary Immune Thrombocytopenia in Spain to better understand the condition and improve how it's treated.

  Recruiting at 29 sites Fundación Española de Hematología y Hemoterapía · A Coruña, A Coruña and 35 other locations · NCT06919341

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.